fludarabine has been researched along with Duncan Disease in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (17.65) | 18.2507 |
| 2000's | 28 (54.90) | 29.6817 |
| 2010's | 14 (27.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bo, J; Cai, B; Gao, C; Han, X; Huang, W; Jing, Y; Li, H; Luo, L; Wang, Q; Yu, L; Zhang, L; Zhao, Y; Zhu, H | 1 |
| Bleesing, JJ; Chandrakasan, S; Davies, SM; Filipovich, AH; Jordan, MB; Marsh, RA | 1 |
| Bittencourt, H; Ceppi, F; Duval, M; Mallette, B; Ovetchkine, P; Teira, P; Therrien, R | 1 |
| Rule, S; Seymour, JF; Shah, N; Tam, C | 1 |
| Bleesing, JJ; Davies, SM; Filipovich, AH; Haines, HL; Hornung, L; Jordan, MB; Marsh, RA | 1 |
| Blaise, D; Ceballos, P; Chevallier, P; Cornelissen, J; Einsele, H; Gluckman, E; Holler, E; Kenzey, C; Linkesch, W; Maillard, N; Pagliuca, A; Pascal, L; Petersen, E; Rocha, V; Ruggeri, A; Sengeloev, H; Tabrizi, R; Tucunduva, L; Yakoub-Agha, I | 1 |
| Ali, M; Chellapandian, D; Gassas, A; Krueger, J; Naqvi, A; Schechter, T; Weitzman, S | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Carney, DA; di Iulio, J; Herbert, KE; Morgan, S; Prince, HM; Seymour, JF; Westerman, DA; Wolf, MM; Yuen, K | 1 |
| Brown, JR; Dal Cin, P; Feng, Y; Fisher, DC; Fisher, RI; Freedman, AS; Friedberg, JW; Joyce, R; Liesveld, J; Marquis, D; Neuberg, D; Phillips, K; Scofield, S; Takvorian, RW | 1 |
| Hoffman, PC | 1 |
| Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ | 1 |
| Tsimberidou, AM | 1 |
| Ahn, HS; Cho, B; Chung, NG; Im, HJ; Kang, HJ; Kim, HK; Kim, SY; Koo, HH; Lee, YH; Lim, YT; Park, JE; Park, SK; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH | 1 |
| Burchette, J; Foo, WC; Huang, Q; Hutchinson, CB; Sebastian, S; Wang, E | 1 |
| Colledan, M; Conter, V; Cornelli, P; Fiocchi, R; Giraldi, E; Provenzi, M; Rambaldi, A; Torre, G | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Agrawal, S; Auer, RL; Cavenagh, JD; Davies, JK; Gribben, JG; Lister, TA; MacDougall, F; Oakervee, HE; Syndercombe-Court, D; Taussig, D | 1 |
| Andreeff, M; Cortes, JE; Faderl, S; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Tsimberidou, AM | 1 |
| Ales, NC; Byrd, JC; Helman, DL; Shorr, AF | 1 |
| Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K | 1 |
| Boudová, L; Cerná, K; Jindra, P; Karas, M; Koza, V; Lysák, D; Svojgrová, M; Vozobulová, V | 1 |
| Kusumi, E; Taniguchi, S | 1 |
| Dlubek, D; Dybko, J; Klimczak, A; Lange, A | 1 |
| Grigg, A; Januszewicz, EH; Matthews, JP; Morgan, SJ; Prince, HM; Seymour, JF; Wolf, MM | 1 |
| Johnson, SA | 2 |
| Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Marotta, G; Raspadori, D | 1 |
| Emerson, SG; Goldstein, SC; Green, J; Loren, AW; Luger, SM; Nasta, SD; Oliver, JC; Orloff, G; Perl, A; Porter, DL; Schuster, S; Stadtmauer, EA; Tsai, DE | 1 |
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Januszewicz, EH; Milner, A; Polizzotto, MN; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE | 1 |
| Decker, T; Fend, F; Götze, KS; Hoffmann, D; Peschel, C; Schätzl, HM | 1 |
| Bonavita, S; Conforti, R; Della Corte, M; Gallo, A; Monsurrò, MR; Russo, A; Sacco, R; Tedeschi, G; Tessitore, A | 1 |
| Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J | 1 |
| Hakimian, D; Tallman, MS | 1 |
| Cheson, BD | 1 |
| Feldman, EJ; Keating, MJ | 1 |
| Pawelski, S | 1 |
| Bolam, S; Orchard, JA; Oscier, DG | 1 |
| Ballerini, F; Beltrami, G; Bruni, R; Canepa, L; Cavaliere, M; Celesti, L; Clavio, M; Congiu, M; Damasio, E; Gobbi, M; Miglino, M; Nati, S; Pierri, I; Pietrasanta, D; Rossi, E; Santini, G; Spriano, M; Vallebella, E; Vimercati, R | 1 |
| Davies, S; Frewin, R; Johnson, S; Rule, S; Tighe, M; Turner, D | 1 |
| Byrd, JC; Diehl, LF; Dow, NA; Hospenthal, DR; Howard, RS; McGrail, LH | 1 |
| Ambinder, RF; Byrd, JC; Diehl, LF; Flinn, IW; Grever, MR; Jamison, J; Morrison, C; Murphy, T; Piantadosi, S; Seifter, E; Vogelsang, G | 1 |
| Leach, M; Parsons, RM; Reilly, JT; Winfield, DA | 1 |
| Harousseau, JL; Mahé, B; Milpied, N; Morin, O; Rapp, MJ; Vigouroux, S | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Bargay, J; Caballero, MD; Canals, C; Conde, JG; Léon, A; Martino, R; Odriozola, J; Rayón, C; San Miguel, J; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A | 1 |
| Abruzzo, LV; Jones, D; Keating, MJ; Luthra, R; Manning, JT; Medeiros, LJ; Rosales, CM; Vega, F | 1 |
| Isaksson, HJ; Mosher, DF; Onundarson, PT; Salamat, MS; Vidarsson, B | 1 |
11 review(s) available for fludarabine and Duncan Disease
| Article | Year |
|---|---|
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoproliferative Disorders; Rituximab; Vidarabine | 2015 |
Immune hemolytic anemia--selected topics.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Blood Group Incompatibility; Cladribine; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Subsets; Lymphoproliferative Disorders; Postoperative Complications; Rituximab; Splenectomy; Transfusion Reaction; Transplantation; Transplantation, Homologous; Venous Thromboembolism; Vidarabine | 2009 |
Ofatumumab in the treatment of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Evidence-Based Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Rituximab; Treatment Outcome; Vidarabine | 2010 |
[Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases].
Topics: Busulfan; Cause of Death; Clinical Trials as Topic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Transplantation Conditioning; Vidarabine | 2003 |
Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance; Humans; Lymphoproliferative Disorders; Pentostatin; Purine Nucleosides; Vidarabine | 1995 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
Fludarabine in the treatment of lymphoproliferative malignancies.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine | 1993 |
[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Remission Induction; Vidarabine | 1995 |
Purine analogues in the management of lymphoproliferative diseases.
Topics: Antineoplastic Agents; Cladribine; Humans; Lymphoproliferative Disorders; Pentostatin; Vidarabine | 1996 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
7 trial(s) available for fludarabine and Duncan Disease
| Article | Year |
|---|---|
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an his
Topics: Adult; Aged; Cell Count; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Recombinant Proteins; Stem Cell Factor; Treatment Outcome; Vidarabine | 2009 |
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Rituximab; Survival Rate; Vidarabine | 2009 |
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine | 2010 |
Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Topics: Adolescent; Adult; Anemia, Aplastic; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Cell Count; Child; Child, Preschool; Cyclophosphamide; Cytomegalovirus Infections; Erythrocyte Transfusion; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Lymphoproliferative Disorders; Male; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prognosis; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2002 |
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
33 other study(ies) available for fludarabine and Duncan Disease
| Article | Year |
|---|---|
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Myeloablative Agonists; Prognosis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Intracellular Signaling Peptides and Proteins; Lymphoproliferative Disorders; Male; Melphalan; Mutation; Myeloablative Agonists; Prognosis; Retrospective Studies; Signaling Lymphocytic Activation Molecule Associated Protein; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2014 |
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphopro
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Calcineurin; Child; Combined Modality Therapy; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Mycophenolic Acid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Male; Melphalan; Mucopolysaccharidoses; Myeloablative Agonists; Retrospective Studies; Severe Combined Immunodeficiency; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Lymphoproliferative Disorders; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child, Preschool; Genetic Diseases, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Melphalan; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative dis
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cell Transformation, Neoplastic; Clone Cells; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Plasma Cells; Vidarabine | 2010 |
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Female; Graft Rejection; Heart Transplantation; Humans; Liver Transplantation; Lymphoproliferative Disorders; Male; Remission Induction; Rituximab; Vidarabine | 2011 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.
Topics: Adult; Aged; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cause of Death; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Lymphoproliferative Disorders; Male; Middle Aged; Risk Factors; Vidarabine | 2002 |
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2003 |
B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen.
Topics: Adult; Antigens, CD; Antigens, CD20; Antilymphocyte Serum; B-Lymphocytes; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphoproliferative Disorders; Male; Middle Aged; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2004 |
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mycophenolic Acid; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2005 |
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Risk Factors; Rituximab; Vidarabine | 2006 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
Topics: Aged; Epstein-Barr Virus Infections; Everolimus; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Vidarabine | 2007 |
Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain; Female; Gadolinium; Humans; Image Enhancement; Leukoencephalopathy, Progressive Multifocal; Lymphoproliferative Disorders; Magnetic Resonance Imaging; Middle Aged; Rituximab; Time; Vidarabine | 2008 |
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine | 2008 |
Association of myelodysplastic changes with purine analogues.
Topics: 2-Chloroadenosine; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxyadenosines; Female; Humans; Lymphoproliferative Disorders; Male; Myelodysplastic Syndromes; Pentostatin; Vidarabine | 1998 |
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm, Residual; Treatment Outcome; Vidarabine | 1998 |
Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.
Topics: Aged; Female; Herpesviridae Infections; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Prospective Studies; Vidarabine | 1999 |
Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Purpura, Thrombocytopenic, Idiopathic; Vidarabine | 2000 |
[Cryptococcus neoformans infection in hematologic malignancies].
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Cryptococcus neoformans; Female; France; Hematologic Neoplasms; Humans; Immunity, Cellular; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Vidarabine | 2000 |
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.
Topics: Adolescent; Adult; Aged; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Karyotyping; Lymphoproliferative Disorders; Male; Middle Aged; Prognosis; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Ribosomal Proteins; RNA-Binding Proteins; Vidarabine | 2002 |
Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.
Topics: Aged; Antineoplastic Agents; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2002 |